Regulus Therapeutics Inc.
RGLS
Peringkat dalam Saham
#17335
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Harga Saham
$8.16
Terakhir disinkronkan: 2025-06-26
Kapitalisasi Pasar
$234.57M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-56.96%
Negara
US
Perdagangan Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Jumlah saham beredar untuk Regulus Therapeutics Inc. (RGLS)
Jumlah saham beredar per March 2024: 150.47M
Menurut laporan keuangan terbaru dan harga saham Regulus Therapeutics Inc., jumlah saham beredar saat ini adalah 150.47M. Pada akhir December 2022, perusahaan memiliki 136.62M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Regulus Therapeutics Inc. (RGLS) dari 2002 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 150.47M | 9.64% |
| 2023 | 137.24M | 0.45% |
| 2022 | 136.62M | 2.26% |
| 2021 | 133.60M | 1.37% |
| 2020 | 131.79M | 4.27% |
| 2019 | 126.40M | 0.83% |
| 2018 | 125.36M | 8.26% |
| 2017 | 115.79M | 9.47% |
| 2016 | 105.77M | 1.15% |
| 2015 | 104.57M | 4.13% |
| 2014 | 100.42M | 2.18% |
| 2013 | 98.28M | 3.83% |
| 2012 | 94.65M | -74.15% |
| 2011 | 366.20M | 1.02% |
| 2010 | 362.50M | 0.85% |
| 2009 | 359.44M | 1.12% |
| 2008 | 355.47M | 4.07% |
| 2007 | 341.56M | 11.55% |
| 2006 | 306.19M | 14.34% |
| 2005 | 267.79M | 8.72% |
| 2004 | 246.31M | 18.44% |
| 2003 | 207.96M | 12.86% |
| 2002 | 184.26M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 68.74% |
US
|
|
| 396.00M | 163.17% |
US
|
|
| 478.91M | 218.27% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -58.67% |
NL
|
